<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03752996</url>
  </required_header>
  <id_info>
    <org_study_id>2011-03</org_study_id>
    <nct_id>NCT03752996</nct_id>
  </id_info>
  <brief_title>ACURATE TF™ Transfemoral Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis (2011-03)</brief_title>
  <acronym>2011-03</acronym>
  <official_title>ACURATE TF™ Transfemoral Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Symetis SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First-In-Man Study on the ACURATE TF™ Transfemoral Aortic Bioprosthesis Implantation in&#xD;
      Patients with Severe Aortic Stenosis to collect human feasibility data pertaining to the&#xD;
      safety and performance of the device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single arm, prospective, multicenter, non-randomized, open trial, up to 5 Years follow-up&#xD;
      with the Symetis ACURATE TF™ Transfemoral Aortic Bioprosthesis for minimal invasive&#xD;
      implantation via transfemoral access to treat patients with severe aortic stenosis where&#xD;
      conventional aortic valve replacement (AVR) via open heart surgery is considered to be&#xD;
      associated with high risk.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 9, 2012</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from all-cause mortality</measure>
    <time_frame>30-Days</time_frame>
    <description>Rate of all-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of MACCE (major cardiac and cerebrovascular event)</measure>
    <time_frame>30-Days and 12-Months</time_frame>
    <description>Rate of major cardiac and cerebrovascular event (MACCE) defined as cardiovascular death, myocardial infarction and stroke</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Aortic Stenosis Symptomatic</condition>
  <arm_group>
    <arm_group_label>ACURATE TF™ Aortic Valve System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACURATE TF™ Aortic Valve System is intended for subjects with severe symptomatic Aortic Stenosis and considered high risk for surgical conventional Aortic Valve Replacement .</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACURATE TF™ Aortic Valve System</intervention_name>
    <description>Transcatheter Aortic Valve Implantation</description>
    <arm_group_label>ACURATE TF™ Aortic Valve System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients 75 years of age and older&#xD;
&#xD;
          2. Logistic EuroSCORE ≥ 20%&#xD;
&#xD;
          3. Severe aortic stenosis characterized by mean aortic gradient &gt; 40 mmHg or peak jet&#xD;
             velocity &gt; 4.0 m/s or aortic valve area &lt; 1.0 cm2&#xD;
&#xD;
          4. New York Heart Association (NYHA) Functional Class &gt; II&#xD;
&#xD;
          5. Aortic annulus diameter from ≥ 21mm up to ≤ 27mm measured by TEE&#xD;
&#xD;
          6. Patient not a surgical candidate due to significant co-morbid conditions unrelated to&#xD;
             aortic stenosis&#xD;
&#xD;
          7. Patient willing to participate in the study and provide signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unicuspid or bicuspid aortic valve&#xD;
&#xD;
          2. Extreme eccentricity of calcification&#xD;
&#xD;
          3. Severe mitral regurgitation ( &gt;2+)&#xD;
&#xD;
          4. Pre-existing prosthetic heart valve in any position and / or prosthetic ring&#xD;
&#xD;
          5. Aortic or peripheral anatomy NOT appropriate for transfemoral implant&#xD;
&#xD;
          6. Thoracic (TAA) or abdominal (AAA) aortic aneurysm&#xD;
&#xD;
          7. Presence of endovascular stent graft for treatment of TAA or AAA&#xD;
&#xD;
          8. Trans-esophageal echocardiogram (TEE) is contraindicated&#xD;
&#xD;
          9. Left Ventricle Ejection Fraction (LVEF) &lt; 30% by echocardiography (ECHO)&#xD;
&#xD;
         10. ECHO evidence of intracardiac mass, thrombus, or vegetation&#xD;
&#xD;
         11. Acute Myocardial Infarction (AMI) within 1 month prior to implant procedure&#xD;
&#xD;
         12. Percutaneous Coronary Intervention (PCI), except for balloon valvuloplasty (BAV)&#xD;
             within 1 month prior to implant procedure&#xD;
&#xD;
         13. Previous Transient Ischemic Attack (TIA) or stroke within 3 months prior to implant&#xD;
             procedure&#xD;
&#xD;
         14. Active ulcer or gastrointestinal (GI) bleeding within 3 months prior to implant&#xD;
             procedure&#xD;
&#xD;
         15. Any scheduled surgical or percutaneous procedure to be performed prior to 30 day visit&#xD;
&#xD;
         16. History of bleeding diathesis or coagulopathy or refusal of blood transfusions&#xD;
&#xD;
         17. Systolic pressure &lt;80 mmHg, cardiogenic shock, need for inotropic support or&#xD;
             Intra-Aortic Balloon Pump (IABP)&#xD;
&#xD;
         18. Primary hypertrophic obstructive cardiomyopathy (HOCM)&#xD;
&#xD;
         19. Active infection, endocarditis or pyrexia&#xD;
&#xD;
         20. Hepatic failure&#xD;
&#xD;
         21. Chronic renal dysfunction with serum creatinine &gt; 2.5 mg/dL or renal dialysis&#xD;
&#xD;
         22. Refusal of surgery&#xD;
&#xD;
         23. Severe Chronic Obstruction Pulmonary Disease (COPD) requiring home oxygen&#xD;
&#xD;
         24. Neurological disease severely affecting ambulation or daily functioning, or dementia&#xD;
&#xD;
         25. Life expectancy &lt; 12 months due to non-cardiac co-morbid conditions&#xD;
&#xD;
         26. Known hypersensitivity/contraindication to study medication, contrast media, or&#xD;
             nitinol&#xD;
&#xD;
         27. Currently participating in an investigational drug or another device study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>Sao Paulo</city>
        <zip>CEP 04012-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik GmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Universitätsklinikum Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 21, 2018</study_first_submitted>
  <study_first_submitted_qc>November 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2018</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

